1,091 projects

Date from new to old

FORNY20-FORNY2020

KVAL: exRayMat Evidence-based shielding device to reduce medical team radiation exposure during procedures.

Based on clinical experience and bench testing the inventors at HUH has developed a simple, flexible, easy to use and low cost x-ray shield. Radiation shielding is mandatory for interventional cardiologists but there is a need to improve efficacy and ease of use. As part of an RCN qualification ...

Awarded: NOK 0.50 mill.

Project Period: 2022-2023

Location: Vestland

PES-HORISONT-EU-PES Horisont Europa

PES-application Woman TechEU - Seald AS Resubmission - above threshold 2021

Sjeldne kreftformer utgjør 20% av all kreft og kjennetegnes ofte av høy dødelighet, mangel på effektive kreftmedisiner og stort udekket medisinsk behov. Kreft i gallegangene, Cholangiocarcinom,CCA, er en slik sjelden kreftform. Internasjonal standard behandling en kombinasjon av to av tre cellegi...

Awarded: NOK 24,999

Project Period: 2022-2023

Location: Oslo

INNO-NAERING-INNO-NAERING

SupaFLEX: Microalgal polysaccharides as a novel treatment for osteoarthritis

Microalgae are microscopic plants found in freshwater and marine environments. Despite their small size, microalgae play a key role as a source of nutrients for oceanic life, and in CO2 capture. MicroA A.S is developing innovative and sustainable microalgal-derived products for a number of market...

Awarded: NOK 5.3 mill.

Project Period: 2022-2025

Location: Rogaland

INNO-NAERING-INNO-NAERING

E!646PRECYSE. Predictive biomarker profile for tumour and patient stratification for CyPep-1 guided ICI-therapy

CyPep-1 is an innovative, first-in-class, tumor membrane targeting immunotherapy. CyPep-1 activates an immune response against cancer cells and increases the effect from other immunotherapies like Immune Checkpoint Inhibitors (ICI) (e.g. anti-PD-1). In this project we will develop and validate Pr...

Awarded: NOK 3.4 mill.

Project Period: 2022-2025

Location: Vestland

INNO-NAERING-INNO-NAERING

E!1826 AI quantification of wake-up stroke

Wake-up stroke - when a patient awakens with stroke symptoms - affects around 25% of stroke patients. The treatment options (thrombectomy and thrombolysis) have high efficacy for stroke, but it can only be administered within a specific time window (<4.5h-6h) after the first symptoms. For wake-up...

Awarded: NOK 1.9 mill.

Project Period: 2022-2025

Location: Oslo

PES-HORISONT-EU-PES Horisont Europa

Women Tech - Entering European systems to help people with migraine

This PES project will support the writing of an application for the Women TechEU call. The writing includes structuring a work package with activities (deliverables, milestones), preparing the proposal and a 5 page business plan. The work includes budgeting of the proposed work package to cover n...

Awarded: NOK 24,999

Project Period: 2022-2023

Location: Oslo

FORNY20-FORNY2020

KVAL: A SUPERCONSTRUCT FOR OSTEOPOROTIC FEMUR FRACTURES

The increasing size of the geriatric population causes an increasing number of complex fractures around an increasing number of hip and knee prosthesis. This project aims to design an implant system that simplifies this complex surgery along with better fixation of the fracture fragments compared...

Awarded: NOK 0.50 mill.

Project Period: 2022-2023

Location: Oslo

HELSEFORSKNING-Helseforskning

Multimodal Approach Targeting treatment Refractory cancers usIng neXt generation technologies and trials

MATRIX is a research center for clinical treatment (FKB) with the ambition to extend lives and improve the quality of life for patients with cancers that are difficult to cure. Each year, more than 38,000 people in Norway are diagnosed with cancer. Although most are cured, cancer remains the lead...

Awarded: NOK 128.0 mill.

Project Period: 2022-2030

Location: Oslo

FRIPROSJEKT-FRIPROSJEKT

Long-term effects of SARS-CoV-2 infection: An interdisciplinary observational and interventional study program

Long-term effects of COVID-19 have become increasingly recognized. Acute lung damage may be followed by chronic impairment of lung function. COVID-19 may also be associated with increased risk of chronic cardiac and vascular injury, and persistent shortness of breath may be a symptom of both pulm...

Awarded: NOK 12.5 mill.

Project Period: 2022-2027

Location: Oslo

PES-HORISONT-EU-PES Horisont Europa

The ANeED IHI Study: Care pathways in Dementia with Lewybodies with comorbid sleep disorders, mental disorders and Alzheimer’s diasease.

In this PES project we will organize a new consortium building on our ANeED Joint Effort21 consortium funded by the NRC by inviting 5 new major clinical DLB centres in Europe and two new industry partners to participate. We will based on our previously successful applications for clinical trials ...

Awarded: NOK 0.50 mill.

Project Period: 2022-2022

Location: Rogaland

NANOTEKNOLOGI-NANOTEKNOLOGI

Engineered nano-based device for glioblastoma multiforme therapy (Nano4Glio)

Nano4Glio is a transnational European project with partners from Portugal (coordinator), Denmark and Norway. The consortium is comprised of experts within design and development of nanocarriers and characterization of nanomedicines, as well as pharmacists and cell biologists. The main goal of th...

Awarded: NOK 5.0 mill.

Project Period: 2022-2025

Location: Trøndelag - Trööndelage

INNO-NAERING-INNO-NAERING

PredARIA - A new biomarker system to predict ARIA adverse side effects from immunotherapies for Alzheimers disease

The US launch of new Alzheimer's Disease (AD) immunotherapies has put the spotlight on a serious side effect named “Amyloid Related Imaging Abnormalities (ARIA)”. AD is an irreversible progressive disorder that slowly destroys memory, thinking and function skills. Recently FDA approved the firs...

Awarded: NOK 11.3 mill.

Project Period: 2022-2025

Location: Oslo

HELSEFORSKNING-Helseforskning

Human brain clearance imaging (HCBI): a window on physiological disturbances in the pre-diagnostic phase of neurodegenerative disease

In the project "Human Brain Clearance Imaging (HBCI): A Window on Physiological Disturbances in the Pre-diagnostic Phase of Neurodegenerative Disease", five European Centers join forces to develop validated, image based biomarkers of brain clearance. Reduced clearance of potentially toxic metabol...

Awarded: NOK 3.0 mill.

Project Period: 2022-2025

Location: Oslo

HELSEFORSKNING-Helseforskning

Dynamics of Affect Modulation in Neurodevelopmental Disorders

The project investigates three common mental disorders that all begin early in life and share the phenomenon of mood fluctuations, i.e. the change between depressive states, euphoric states and neutral mood: ADHD, borderline personality disorder and bipolar disorder. Attention deficit/hyperactiv...

Awarded: NOK 3.0 mill.

Project Period: 2022-2026

Location: Vestland

FORNY20-FORNY2020

KVAL: A kit for molecular imaging of kidney function using Positron Emission Tomography

We have developed a novel concept to visualize and quantify single kidney function direct, fast and with superior selectivity without the need for blood or urine sampling. The invention decreases the time required for investigating kidney filtration function from multiple hours or days down to mi...

Awarded: NOK 0.50 mill.

Project Period: 2022-2022

Location: Vestland

BIOTEK2021-Bioteknologi for verdiskaping

Arr: Partnerskap arr. - Internasjonalisering av forskningsbasert innovasjon innen livsvitenskap som springer ut fra norske UH-institusjoner

Forskningsbasert-innovasjon innenfor livsvitenskap som springer ut fra norske UH-institusjoner møter internasjonal konkurranse fra dag én og det fremtidige markedet er internasjonalt. Innenfor bioteknologi og pharma er USA et av de største markedene for industriell forskning og utvikling, og for ...

Awarded: NOK 95,999

Project Period: 2022-2023

Location: Oslo

FORNY20-FORNY2020

KVAL: A novel drug for pancreatic cancer

A novel drug for pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer, has a poor outcome with a five-year survival rate of about 8%. Despite extended effort, the five-year survival rate has only marginally improved over the past 45 years due to th...

Awarded: NOK 0.50 mill.

Project Period: 2022-2023

Location: Oslo

PES-HORISONT-EU-PES Horisont Europa

FlowOx 3.0 NEURO

FlowOx is an innovative non-invasive medical device that will disrupt decades of inadequate drug-based therapies with a novel approach to the medical practice and for the treatment of symptomatic pain and muscle spasms in MS patients. The mechanism of action will involve vascularly induced neuro...

Awarded: NOK 74,999

Project Period: 2022-2023

Location: Oslo

FORNY20-FORNY2020

KVAL: Automated quantification of body composition from CT scans

BodySegAI – Artificial intelligence to measure muscle mass in cancer patients BodySegAI measures muscle and different types of fat in cancer patients using already existing CT-scans. Integration of BodySegAI in the hospital workflow can enable individual tailoring of cancer treatment, in additio...

Awarded: NOK 0.34 mill.

Project Period: 2022-2023

Location: Oslo

FORNY20-FORNY2020

KVAL: Prostate cancer classifier

Prostate cancer is the leading cancer in Norway, with approximately 1000 deaths annually. Most patients have non-metastatic cancer, and surgical removal of the prostate gland is a common treatment. Unfortunately, a significant number of patients experience disease relapse, highlighting the need f...

Awarded: NOK 0.50 mill.

Project Period: 2022-2023

Location: Oslo

HELSEFORSKNING-Helseforskning

Artificial intelligence for personalised medicine in depression

Psychiatric diseases affect several hundred million people world-wide. Most prevalent is depression, which causes great suffering of both patients and families, as well as high societal costs associated with sick leaves and treatment requirements. Treatment of depression often involve use of anti...

Awarded: NOK 3.0 mill.

Project Period: 2022-2026

Location: Oslo

HELSEVEL-Gode og effektive helse-, omsorgs- og velferdstjenester

Riktig legemiddelbruk hos pasienter med psykisk utviklingshemming - et innovasjonsprosjekt med potensielt stor nasjonal verdi

Legemiddelbruk til brukere med psykisk utviklingshemming oppleves som utfordrende. Det er flere grunner til dette, både utfordringer med å holde oversikt over legemiddelbruken (samstemming), elektroniske systemer som skal kommunisere med hverandre, kommunikasjon mellom helsepersonell, samt vedlik...

Awarded: NOK 0.15 mill.

Project Period: 2022-2022

Location: Nordland - Nordlánnda

HELSEFORSKNING-Helseforskning

Algorithm of Graft Outcome in Renal Allotransplantation

Kidney transplant recipients must use immunosuppressive drugs for the rest of their lives to prevent the body from rejecting the new kidney. The immunosuppressive drugs unfortunately have a number of side effects and it is therefore important that these are dosed as low as possible. Exactly where...

Awarded: NOK 3.1 mill.

Project Period: 2022-2026

Location: Oslo

INNO-NAERING-INNO-NAERING

E!132 - A novel ultrabroad-spectrum ß-lactamase inhibitor (BLI) to secure the efficacy of antibiotics against Gram-negative pathogens

The SECURE project is a collaborative project between four partners in Norway, Sweden and Denmark, headed by Adjutec. Due to overuse of antibiotics, pathogenic bacteria are now increasingly able to defend themselves against antibiotics. Antibiotics are vital medicines in the treatment of infectio...

Awarded: NOK 5.8 mill.

Project Period: 2022-2025

Location: Oslo

EUROSTARS-EUROSTARS

E! LiverPRO - algoritme for bedre diagnostikk av behandlingskrevende fettlever

Liver disease has become one of the important causes of death in the world. Steatotic liver disease, (SLD), which in the worst case ends with cirrhosis, has traditionally been associated with high consumption of alcohol. There is now a significant increase in the proportion of patients who develo...

Awarded: NOK 1.5 mill.

Project Period: 2022-2024

Location: Rogaland

HELSEFORSKNING-Helseforskning

Subpopulation heterogeneitY and MicroenvironMental Engagement as predictors for Treatment Resistance in lYmphoma

Lymphomas, like most other cancers, consist of multiple distinct cancer cell populations within each patient. These tumor subpopulations have distinct genetic and biological characteristics leading to different drug response profiles. The aim of this project is to characterize these tumor subpopu...

Awarded: NOK 3.1 mill.

Project Period: 2022-2025

Location: Oslo

FORNY20-FORNY2020

KVAL: Deep learning in dynamic Possitron Emission Tomography (PET) Imaging

Medical imaging is widely used to visualize tissue, tumors and biological processes both clinically in disease diagnosis and in animals for research purposes. There are different types of medical imaging where some focus on visualizing anatomical structures or tissues (ex CT, MRI ) while others v...

Awarded: NOK 0.50 mill.

Project Period: 2022-2022

Location: Troms - Romsa - Tromssa

HELSEFORSKNING-Helseforskning

MULTIDISCIPLINARY RESEARCH PROJECTS ON PERSONALISED MEDICINE; DEVELOPMENT OF CLINICAL SUPPORT TOOLS FOR PERSONALISED MEDICINE IMPLEMENTATION

ScandRA is a Scandinavian collaboration building on several years of research within the Nordic countries. We have used clinical data from several cohorts of patients with rheumatoid arthritis (RA) from the three Scandinavian countries to explore prediction and developing new algorithms for evalu...

Awarded: NOK 2.9 mill.

Project Period: 2022-2025

Location: Oslo

FORNY20-FORNY2020

Tankyrase inhibition as a therapeutic principle in idiopathic lung fibrosis

We aim to develop the OUS proprietary tankyrase inhibitor OM-0815 as a new treatment for lung scarring (fibrosis). Interstitial lung disease, is an umbrella term for multiple diseases causing lung fibrosis, and includes idiopathic pulmonary fibrosis with an unknown origin. Idiopathic pulmonary fi...

Awarded: NOK 5.0 mill.

Project Period: 2022-2023

Location: Oslo

FORNY20-FORNY2020

KVAL: Tuned CAR-T cells – a novel platform technology

Cellular cancer treatment with CAR-Ts is by many regarded as the future of oncology. But so far, not many CAR-Ts have succeeded in the clinic. One of the reasons for this is that oftentimes the T-cells have a CAR which can kill the T-cell itself even before it can kill the cancer cell. Scientists...

Awarded: NOK 0.50 mill.

Project Period: 2022-2023

Location: Oslo

1 5 6 7 8 9 37